$SPHS watching how positive phase 3 prostate triall news does to a stock like Myovant, now with a market cap of 1.5 Billion. If topsalysin gets through the finish line imagine how much it can be worth. If Randall doesn’t get more than 300 million for topsalysin, I would rather him and the company do a Phase 3 themselves. They have to be able to get a tranche loan for the 50 million they need. Companies with less promising drugs have gotten more than 50 million in tranche loans. #SorryRandallWoods
  • 2
  • 5